Tushar Manudhane · Motilal Oswal Financial Services Ltd
evasiveClarification on full year FY26 growth guidance
It is in line with what we said, maintains growth for the whole year.
AJANTPHARM / Q3-FY26 / claim-ledger
Audit the questions that mattered.
Ajanta Pharma · Analyst questions, management answers, and the quality of the response where the ledger is available.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Questions audited
12
Answered directly
54%
Numeric claims
1
Consistency
contradicted
Question ledger
What was answered, and how?
Tushar Manudhane · Motilal Oswal Financial Services Ltd
directExplanation for gross margin improvement and sustainability
I think, what I just mentioned, I think, you should consider 78%, ±1%. Some variations keep on happening quarter to quarter, but overall, I think we are very confident that we should be able to maintain it at about 78%, ±1%.
Tushar Manudhane · Motilal Oswal Financial Services Ltd
partialOutlook for US business in FY27
It should be good only, but I think it will be a bit early to give the guidance for that. I think let's do that in the next quarter... we should be able to post, double-digit growth for sure.
Tushar Manudhane · Motilal Oswal Financial Services Ltd
declinedConstant currency growth for US business in Q3 and 9M FY26
I think I don't have that figure right now. ... I will give it, share it later.
Abdulkader Puranwala · ICICI Securities Limited
directDrivers of India business 19% growth outperformance
No, I think it's mostly a little bit of seasonal also for us in some sense. But at the same time, we have had some very good activities... gynecology has done much better... Dermatology... outperformed the market by nearly two times the growth rate.
Abdulkader Puranwala · ICICI Securities Limited
directDeployment of 150 new MRs and GLP-1 launch plans
Number of reps, what we have added in domestic are across these four therapeutic segments, and that is basically Pan India. ... For GLP, we will be launching in India under our own trademark, and, we hope to be in the first wave of the product launches that will happen, in the month of March.
Abdulkader Puranwala · ICICI Securities Limited
directDetails of Biocon partnership for GLP-1 overseas
So the arrangement will be that, they will be supplying to us the finished product. ... we have tied up with them for 26 countries, where 23 is exclusive tie-up with us. ... we are looking to start filing the dossiers from, Q1 in all our markets, and, from 12 months onwards, we should start getting the approvals.
Abdulkader Puranwala · ICICI Securities Limited
evasiveFinancial terms of Biocon partnership (profit share/upfront fee)
There is some confidentiality agreements which we have in place, so I'm not able to give the exact details, but it's a combination of all what we have just mentioned.
Aman Kumar Singh · Research desk
evasiveDividend payout ratio expectation for FY26
I think it is still not decided because there is one more quarter which is going to be there. ... we are increasing our thrust on the acquisition. So if that happens, then in that case, maybe board will advise accordingly.
Kashish Thakur · Elara Capital
directBreakup of India growth: volume, price, new products
So volume growth, IPM is at 2.1%. This is a composition of 8.9% IPM growth. Ajanta has grown at 3.1%... And, for the new products, IPM has shown a contribution of 2.5% in the growth, and Ajanta has shown 3.9%.
Foram Parekh · Bank of Baroda Capital Markets
declinedMarkets causing softness in Asia business
Unfortunately, we don't give such granular details of the country-wise or things like that.
Foram Parekh · Bank of Baroda Capital Markets
directGuidance for Asia and Africa branded business FY26
So I think Asia, we should be able to post mid-single digit to high single digit. ... For Africa, we should probably post in low double digit, I think.